Turn Therapeutics Inc.
TTRX
$13.90
$1.249.80%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -11.57% | 202.56% | 576.25% | 237.68% | 355.56% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 65.88% | 347.74% | 717.78% | 184.34% | 279.37% |
| Operating Income | -65.88% | -347.74% | -717.78% | -184.34% | -279.37% |
| Income Before Tax | -371.60% | -195.59% | 186.38% | -185.74% | -252.49% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -371.60% | -195.59% | 186.38% | -185.74% | -252.49% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -371.60% | -195.59% | 186.38% | -185.74% | -252.49% |
| EBIT | -65.88% | -347.74% | -717.78% | -184.34% | -279.37% |
| EBITDA | -66.34% | -358.75% | -745.36% | -187.47% | -288.30% |
| EPS Basic | -335.48% | -169.67% | 181.67% | -172.40% | -239.10% |
| Normalized Basic EPS | -335.11% | -171.05% | 181.33% | -172.44% | -239.76% |
| EPS Diluted | -335.48% | -169.67% | 181.67% | -172.40% | -239.10% |
| Normalized Diluted EPS | -335.11% | -171.05% | 181.33% | -172.44% | -239.76% |
| Average Basic Shares Outstanding | 8.34% | 9.35% | 5.54% | 4.99% | 3.76% |
| Average Diluted Shares Outstanding | 8.34% | 9.35% | 5.54% | 4.99% | 3.76% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |